106 related articles for article (PubMed ID: 24468412)
1. Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
Shea TA; Burburan PJ; Matubia VN; Ramcharan SS; Rosario I; Parkin DW; Stockman BJ
Bioorg Med Chem Lett; 2014 Feb; 24(4):1080-4. PubMed ID: 24468412
[TBL] [Abstract][Full Text] [Related]
2. Antiprotozoal activity of proton-pump inhibitors.
Pérez-Villanueva J; Romo-Mancillas A; Hernández-Campos A; Yépez-Mulia L; Hernández-Luis F; Castillo R
Bioorg Med Chem Lett; 2011 Dec; 21(24):7351-4. PubMed ID: 22047694
[TBL] [Abstract][Full Text] [Related]
3. Adenosine/guanosine preferring nucleoside ribohydrolase is a distinct, druggable antitrichomonal target.
Beck S; Muellers SN; Benzie AL; Parkin DW; Stockman BJ
Bioorg Med Chem Lett; 2015 Nov; 25(22):5036-9. PubMed ID: 26592812
[TBL] [Abstract][Full Text] [Related]
4. Ligand-Efficient Inhibitors of Trichomonas vaginalis Adenosine/Guanosine Preferring Nucleoside Ribohydrolase.
Muellers SN; Gonzalez JA; Kaur A; Sapojnikov V; Benzie AL; Brown DG; Parkin DW; Stockman BJ
ACS Infect Dis; 2019 Mar; 5(3):345-352. PubMed ID: 30701958
[TBL] [Abstract][Full Text] [Related]
5. [In vitro susceptibility of Trichomonas vaginalis to metronidazole, ornidazole and proton pump inhibitors pantoprazole and esomeprazole].
Aksoy Gökmen A; Girginkardeşler N; Kilimcioğlu AA; Şirin MC; Özbilgin A
Mikrobiyol Bul; 2016 Jan; 50(1):133-9. PubMed ID: 27058337
[TBL] [Abstract][Full Text] [Related]
6. Druggability of the guanosine/adenosine/cytidine nucleoside hydrolase from Trichomonas vaginalis.
Alam R; Barbarovich AT; Caravan W; Ismail M; Barskaya A; Parkin DW; Stockman BJ
Chem Biol Drug Des; 2018 Oct; 92(4):1736-1742. PubMed ID: 29808562
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in chirally pure proton pump inhibitors.
Pai V; Pai N
J Indian Med Assoc; 2007 Aug; 105(8):469-70, 472, 474. PubMed ID: 18236913
[TBL] [Abstract][Full Text] [Related]
8. Negative chronotropic effect of proton pump inhibitors on frog-heart preparation.
Gautam CS; Utreja A; Goel D; Sandhu G; Gogia N
Indian J Gastroenterol; 2009; 28(4):147-9. PubMed ID: 19937171
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
Bi Y; Might M; Vankayalapati H; Kuberan B
Bioorg Med Chem Lett; 2017 Jul; 27(13):2962-2966. PubMed ID: 28512024
[TBL] [Abstract][Full Text] [Related]
11. Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
Terranova C; Petrella C; Improta G; Severini C; Signore F; Damiani P; Plotti F; Scarpignato C; Angioli R
Eur J Pharm Sci; 2014 Feb; 52():125-31. PubMed ID: 24215738
[TBL] [Abstract][Full Text] [Related]
12. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
Sharara AI
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
[TBL] [Abstract][Full Text] [Related]
13. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Cuisset T; Frere C; Quilici J; Poyet R; Gaborit B; Bali L; Brissy O; Morange PE; Alessi MC; Bonnet JL
J Am Coll Cardiol; 2009 Sep; 54(13):1149-53. PubMed ID: 19761935
[TBL] [Abstract][Full Text] [Related]
14. Reaction of proton pump inhibitors with model peptides results in novel products.
Watson C; Zhu L; Guan S; Machen TE; Forte JG
J Pharmacol Sci; 2013; 122(3):213-22. PubMed ID: 23877017
[TBL] [Abstract][Full Text] [Related]
15. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C
J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900
[TBL] [Abstract][Full Text] [Related]
16. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Akter S; Hassan MR; Shahriar M; Akter N; Abbas MG; Bhuiyan MA
Alzheimers Res Ther; 2015 Dec; 7():79. PubMed ID: 26714488
[TBL] [Abstract][Full Text] [Related]
17. Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium.
Sossalla S; Schotola H; Schmitto J; Toischer K; Sohns C; Schwörer H; Hasenfuss G; Maier L; Schillinger W
J Cardiovasc Surg (Torino); 2011 Jun; 52(3):437-44. PubMed ID: 21577199
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel and proton pump inhibitors.
Bhatt DL
CMAJ; 2014 Feb; 186(3):213. PubMed ID: 24549709
[No Abstract] [Full Text] [Related]
19. Omeprazole, lansoprazole and pantoprazole had no effect on blood pressure and electrocardiogram of anesthetized rat.
Yenişehirli A; Naseri E
Pharmacol Res; 2008 Jul; 58(1):65-71. PubMed ID: 18647653
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter.
Yurtsever AS; Pektas M; Ozkur M; Un I; Erenmemisoglu A; Buyukafsar K
J Pharm Pharmacol; 2011 Oct; 63(10):1295-300. PubMed ID: 21899545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
